Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fengliao Changweikang is a Traditional Chinese Medicine (TCM) formulation composed of extracts from the leaves of *Liquidambar formosana* Hance and the herb *Polygonum hydropiper* L. It is primarily indicated for the treatment of gastrointestinal disorders, including acute gastroenteritis, acute diarrhea, and functional dyspepsia, particularly those categorized under the damp-heat syndrome in TCM. The drug is recognized for its anti-inflammatory, analgesic, and antibacterial properties, and it is commonly administered in granule form. It is widely marketed in China and has been the subject of clinical trials evaluating its efficacy in adult acute diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fengliao changweikang.